Original Research
Accepted on 28 Nov 2023
A Tumor-Restricted Glycoform of Podocalyxin is a Highly Selective Marker of Immunologically Cold High-Grade Serous Ovarian Carcinoma
Frontiers in Oncology
doi 10.3389/fonc.2023.1286754
Volumes
25,560 Publications
Volume 13 - 2023
Original Research
Accepted on 28 Nov 2023
Prognostic and predictive effects of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
Frontiers in Oncology
doi 10.3389/fonc.2023.1288468
Original Research
Accepted on 28 Nov 2023
Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment
Frontiers in Oncology
doi 10.3389/fonc.2023.1308313
Review
Accepted on 28 Nov 2023
Epigenetic targeting of autophagy for cancer: DNA and RNA methylation
Frontiers in Oncology
doi 10.3389/fonc.2023.1290330
Opinion
Accepted on 28 Nov 2023
Primary Synovial Sarcomas of the Bone: Clinical Perspectives and Correlation Between the Application of SS18-SSX and Decalcification Status
Frontiers in Oncology
doi 10.3389/fonc.2023.1265824
Original Research
Accepted on 28 Nov 2023
T-cell receptor determinants of response to chemoradiation in locallyadvanced HPV16-driven malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1296948
Original Research
Accepted on 28 Nov 2023
Cost-Effectiveness Analysis of Elacestrant versus Standard Endocrine Therapy for Second-/Third-Line Treatment of Patients with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
Frontiers in Oncology
doi 10.3389/fonc.2023.1272586
Correction
Accepted on 28 Nov 2023
Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy
Frontiers in Oncology
doi 10.3389/fonc.2023.1302413
Original Research
Accepted on 28 Nov 2023
Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia
Frontiers in Oncology
doi 10.3389/fonc.2023.1276352
Original Research
Accepted on 28 Nov 2023
Serum Vascular Adhesion Protein-1 is Associated with Twelve-year Risk of Incident Cancer, Cancer Mortality, and All-cause Mortality: a Community-based Cohort Study
Frontiers in Oncology
doi 10.3389/fonc.2023.1308353
Original Research
Accepted on 28 Nov 2023
Enhancing Oral Squamous Cell Carcinoma Prediction: The Prognostic Power of The Worst Pattern of Invasion and the Limited Impact of Molecular Resection Margins
Frontiers in Oncology
doi 10.3389/fonc.2023.1287650
Original Research
Accepted on 28 Nov 2023
TICRR serves as a prognostic biomarker in lung adenocarcinoma with implications in RNA epigenetic modification, DDR pathway, and RNA metabolism
Frontiers in Oncology
doi 10.3389/fonc.2023.1274439
Original Research
Accepted on 28 Nov 2023
Predicting Delayed Remission in Cushing's Disease using Radiomics Models: A Multi-center Study
Frontiers in Oncology
doi 10.3389/fonc.2023.1218897
Original Research
Accepted on 28 Nov 2023
Comparison of reduced field-of-view DWI and conventional DWI techniques for the assessment of lumbar bone marrow infiltration in patients with acute leukemia
Frontiers in Oncology
doi 10.3389/fonc.2023.1321080
Methods
Accepted on 28 Nov 2023
The microRNA target site profile is a novel biomarker in the immunotherapy response
Frontiers in Oncology
doi 10.3389/fonc.2023.1225221
Review
Accepted on 28 Nov 2023
Review: Therapeutic Approaches for Circadian Modulation of the Glioma Microenvironment
Frontiers in Oncology
doi 10.3389/fonc.2023.1295030